# Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

> **NCT04626947** · PHASE4 · TERMINATED · sponsor: **David Binion, MD** · enrollment: 19 (actual)

## Conditions studied

- Inflammatory Bowel Diseases
- Ulcerative Colitis
- Crohn Disease
- C. Diff. Infections

## Interventions

- **BIOLOGICAL:** Bezlotoxumab

## Key facts

- **NCT ID:** NCT04626947
- **Lead sponsor:** David Binion, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-14
- **Primary completion:** 2024-04-24
- **Final completion:** 2024-05-31
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2025-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04626947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04626947, "Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04626947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*